Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Metabolism and Murine Pharmacokinetics of the 8-(N,N-Dimethylcarboxamide) Analogue of the Experimental Antitumor Drug Mitozolomide (NSC353451)

Keith R. Horspool, Charmaine P. Quarterman, John A. Slack, Andreas Gescher, Malcolm F. G. Stevens and Edward Lunt
Keith R. Horspool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charmaine P. Quarterman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Slack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Gescher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malcolm F. G. Stevens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Lunt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published September 1989
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The in vitro cytotoxicity, stability, and metabolism of the 8-(N,N-dimethylcarboxamide) and 8-(N-methylcarboxamide) analogues of the experimental antitumor drug mitozolomide have been investigated in conjunction with their in vivo murine pharmacokinetics and metabolism.

When tested against the TLX5 lymphoma in vitro the ID50 values for dimethylmitozolomide, methylmitozolomide, and mitozolomide were 14.6, 3.0, and 2.3 µm, respectively. The cytotoxicity of dimethylmitozolomide was dramatically increased when it was incubated with murine hepatic microsomes. There was no significant difference in the in vitro stabilities of dimethylmitozolomide and methylmitozolomide with half-lives of 43.5 and 45.8 min, respectively, in RPMI at 37°C. The in vitro microsomal incubation of dimethylmitozolomide produced significant amounts of methylmitozolomide, which suggests that methylmitozolomide contributed to the cytotoxicity of dimethylmitozolomide in the presence of microsomes.

The pharmacokinetics of both dimethylmitozolomide and methylmitozolomide, given i.p. at 10 mg/kg, were investigated in CBA/Ca mice bearing the s.c. solid TLX5 lymphoma. Methylmitozolomide was absorbed rapidly with maximum plasma and tumor concentrations of 10.66 mg/liter and 8.01 mg/kg, respectively, achieved 0.17 h following dosing. Dimethylmitozolomide was also rapidly absorbed with maximum plasma and tumor concentrations of 9.34 mg/liter and 5.00 mg/kg, respectively, achieved within 0.18 h of dosing. Following administration of dimethylmitozolomide, methylmitozolomide was found in both plasma and tumor tissue. The plasma and tumor area under the curves of methylmitozolomide were 87.7% and 120.8%, respectively, of those seen when mice were dosed with authentic methylmitozolomide. By comparison of the area under the curves and clearance values, it was demonstrated that 89% of the administered dimethylmitozolomide was metabolized via methylmitozolomide.

Footnotes

  • ↵1 This study was generously supported by Grant SP1518 from the Cancer Research Campaign of Great Britain and also by a CASE studentship (to K. R. H.) from the Science and Engineering Council in collaboration with May & Baker Ltd. This is Part 19 of the series “Antitumor Imidazotetrazines.” Part 18 is Ref. 1.

  • ↵2 To whom requests for reprints should be addressed.

  • Received August 2, 1988.
  • Revision received January 30, 1989.
  • Revision received March 29, 1989.
  • Accepted June 8, 1989.
  • ©1989 American Association for Cancer Research.
PreviousNext
Back to top
September 1989
Volume 49, Issue 18
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Murine Pharmacokinetics of the 8-(N,N-Dimethylcarboxamide) Analogue of the Experimental Antitumor Drug Mitozolomide (NSC353451)
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Metabolism and Murine Pharmacokinetics of the 8-(N,N-Dimethylcarboxamide) Analogue of the Experimental Antitumor Drug Mitozolomide (NSC353451)
Keith R. Horspool, Charmaine P. Quarterman, John A. Slack, Andreas Gescher, Malcolm F. G. Stevens and Edward Lunt
Cancer Res September 15 1989 (49) (18) 5023-5026;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Metabolism and Murine Pharmacokinetics of the 8-(N,N-Dimethylcarboxamide) Analogue of the Experimental Antitumor Drug Mitozolomide (NSC353451)
Keith R. Horspool, Charmaine P. Quarterman, John A. Slack, Andreas Gescher, Malcolm F. G. Stevens and Edward Lunt
Cancer Res September 15 1989 (49) (18) 5023-5026;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Laminin Receptor Complementary DNA-deduced Synthetic Peptide Inhibits Cancer Cell Attachment to Endothelium
  • T-Cell Receptor Vβ Gene Expression Differs in Tumor-infiltrating Lymphocytes within Primary and Metastatic Melanoma
  • Acidic and Basic Fibrolast Growth Factors Are Present in Glioblastoma Multiforme
Show more Basic Sciences

Articles

  • Laminin Receptor Complementary DNA-deduced Synthetic Peptide Inhibits Cancer Cell Attachment to Endothelium
  • T-Cell Receptor Vβ Gene Expression Differs in Tumor-infiltrating Lymphocytes within Primary and Metastatic Melanoma
  • Acidic and Basic Fibrolast Growth Factors Are Present in Glioblastoma Multiforme
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement